Table 1. Responses to GLIPR1 4–12 and EpCAM 140–148 incases and controls, and HLA restriction studies.
| ND2>5 STD over mock | ND3>5 STD over mock ND3 | ||||
| spot # | gene | Pool #l | spot # | gene | Pool #l |
| 131 | SORL1 | 137 | 145 | HPN/TTFG3 | 35 |
| 35 | OLFM4/ENO2 | 249 | 51 | TOB1/PTPRN | 289 |
| 32 | CPE/CUZD1/NPY | 330 | 50 | ns SNP pool #361 | 361 |
| 29 | WNT4/RAMP2/APOH | 349 | 38 | SERPINA3/PPPIR1A | 103 |
| 27 | ACPP/GLIPR1 | 85 | 38 | PNLIPRP2/PRPH | 337 |
| 26 | SCG2 | 263 | 28 | PTPRN | 290 |
| 22 | APLP1/EPCAM | 308 | 25 | GLIPR1/DNAJC12/STC1 | 87 |
| 21 | PRPH/VGF | 340 | 22 | SCG3/ELL2 | 9 |
| 19 | SYT13/FOXA1 | 2 | 22 | CLDN7/KCNMB2/ATP2A3 | 297 |
| 18 | SCG3/ELL2 | 9 | 21 | C6 | 301 |
| 16 | SERPINA3/PPPIR1A | 104 | 19 | PPPIR1A | 106 |
| 13 | PPPIR1A | 106 | 19 | INPP5E | 27 |
| 13 | PAPSS2/ELA2A | 194 | |||
| 12 | MNX1/CXCL2/CTRB2 | 296 | |||
| 12 | ns SNP pool # 369 | 369 | |||
| 11 | SERPINA3/PPPIR1A | 103 | |||
| 11 | PROM1 | 253 | |||
| 11 | CLDN7/KCNMB2/ATP2A3 | 298 | |||
| 10 | OLFM4/ENO2 | 250 |
Spot number and minigene source for provisionally positive minigene pools. Each score represents a single cultured ELISPOT well stimulated with minigenes derived from the indicated genes. Minigenes in each pool are listed in Table S2. Positive scores exceeded 5 standard deviations of mean scores of wells stimulated with mock transfected autologous B cells. Pool number 9, 103 and 106 scored positive in both subjects.